ATP13A2

Across TCGA pan-cancer cohorts, ATP13A2 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated ATP13A2 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATP13A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP13A2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and OV are the cancer types where ATP13A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.156	0.743	.001	36	view →
UCEC	DFS	Median	II,III,IV	1.000	0.440	.021	20	view →
OV	DFS	Median	All	0.305	0.542	.037	18	view →
READ	OS	Median	III,IV	0.289	0.932	<.001	15	view →
ACC	OS	Median	All	0.147	0.685	.018	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
COAD	DFS	Median	All	0.177	0.702	<.001	7	view →
GBM	OS	Median	All	0.030	0.416	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.309	0.620	.033	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

ATP13A2–HNSC (OS)

Open the HNSC breakdown →